^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy

    Published date:
    05/01/2020
    Excerpt:
    Our retrospective study provides clinical evidence that combined targeted therapy of brigatinib and cetuximab could provide benefit and may potentially be an effective treatment strategy to improve survival outcomes of patients who acquired EGFR T790M/cis-C797S-mediated resistance to osimertinib.
    DOI:
    10.1016/j.jtho.2020.04.014